nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—PTGS1—Sulfasalazine—rheumatoid arthritis	0.048	0.124	CbGbCtD
Bortezomib—CYP1A2—Leflunomide—rheumatoid arthritis	0.0347	0.0898	CbGbCtD
Bortezomib—CYP2C9—Leflunomide—rheumatoid arthritis	0.0313	0.0809	CbGbCtD
Bortezomib—CYP1A1—Dexamethasone—rheumatoid arthritis	0.024	0.0619	CbGbCtD
Bortezomib—CYP2C8—Hydrocortisone—rheumatoid arthritis	0.0222	0.0575	CbGbCtD
Bortezomib—CYP2C8—Cyclosporine—rheumatoid arthritis	0.021	0.0543	CbGbCtD
Bortezomib—CYP3A4—Ergocalciferol—rheumatoid arthritis	0.0201	0.052	CbGbCtD
Bortezomib—CYP2C19—Prednisone—rheumatoid arthritis	0.0186	0.048	CbGbCtD
Bortezomib—CYP2C19—Cyclosporine—rheumatoid arthritis	0.0176	0.0455	CbGbCtD
Bortezomib—CYP3A4—Methylprednisolone—rheumatoid arthritis	0.0148	0.0383	CbGbCtD
Bortezomib—CYP2C9—Cyclosporine—rheumatoid arthritis	0.0147	0.0379	CbGbCtD
Bortezomib—CYP2C8—Dexamethasone—rheumatoid arthritis	0.0138	0.0357	CbGbCtD
Bortezomib—CYP2D6—Cyclosporine—rheumatoid arthritis	0.0134	0.0346	CbGbCtD
Bortezomib—CYP2C19—Dexamethasone—rheumatoid arthritis	0.0116	0.03	CbGbCtD
Bortezomib—CYP3A4—Triamcinolone—rheumatoid arthritis	0.0112	0.0291	CbGbCtD
Bortezomib—CYP2C9—Dexamethasone—rheumatoid arthritis	0.00965	0.0249	CbGbCtD
Bortezomib—CYP3A4—Betamethasone—rheumatoid arthritis	0.00965	0.0249	CbGbCtD
Bortezomib—CYP3A4—Prednisolone—rheumatoid arthritis	0.00952	0.0246	CbGbCtD
Bortezomib—CYP3A4—Hydrocortisone—rheumatoid arthritis	0.00902	0.0233	CbGbCtD
Bortezomib—CYP3A4—Prednisone—rheumatoid arthritis	0.00899	0.0232	CbGbCtD
Bortezomib—CYP2D6—Dexamethasone—rheumatoid arthritis	0.00882	0.0228	CbGbCtD
Bortezomib—CYP3A4—Cyclosporine—rheumatoid arthritis	0.00852	0.022	CbGbCtD
Bortezomib—CYP3A4—Dexamethasone—rheumatoid arthritis	0.00561	0.0145	CbGbCtD
Bortezomib—CTSG—connective tissue—rheumatoid arthritis	0.00371	0.045	CbGeAlD
Bortezomib—PSMA1—connective tissue—rheumatoid arthritis	0.00356	0.0432	CbGeAlD
Bortezomib—PSMD1—parotid gland—rheumatoid arthritis	0.0034	0.0412	CbGeAlD
Bortezomib—PSMD1—saliva-secreting gland—rheumatoid arthritis	0.00325	0.0395	CbGeAlD
Bortezomib—PSMD2—parotid gland—rheumatoid arthritis	0.00301	0.0365	CbGeAlD
Bortezomib—PSMB8—parotid gland—rheumatoid arthritis	0.00299	0.0363	CbGeAlD
Bortezomib—PSMD2—saliva-secreting gland—rheumatoid arthritis	0.00288	0.035	CbGeAlD
Bortezomib—PSMB8—saliva-secreting gland—rheumatoid arthritis	0.00287	0.0347	CbGeAlD
Bortezomib—CTSG—lymphoid tissue—rheumatoid arthritis	0.00271	0.0329	CbGeAlD
Bortezomib—PSMB5—parotid gland—rheumatoid arthritis	0.00264	0.032	CbGeAlD
Bortezomib—PSMA1—lymphoid tissue—rheumatoid arthritis	0.0026	0.0316	CbGeAlD
Bortezomib—PSMA1—digestive system—rheumatoid arthritis	0.00257	0.0312	CbGeAlD
Bortezomib—CTSG—tendon—rheumatoid arthritis	0.00255	0.0309	CbGeAlD
Bortezomib—PSMB5—saliva-secreting gland—rheumatoid arthritis	0.00253	0.0307	CbGeAlD
Bortezomib—PSMB1—parotid gland—rheumatoid arthritis	0.00231	0.028	CbGeAlD
Bortezomib—PSMB2—parotid gland—rheumatoid arthritis	0.00225	0.0273	CbGeAlD
Bortezomib—PSMB1—saliva-secreting gland—rheumatoid arthritis	0.00221	0.0268	CbGeAlD
Bortezomib—PSMB2—saliva-secreting gland—rheumatoid arthritis	0.00216	0.0262	CbGeAlD
Bortezomib—PSMD1—tendon—rheumatoid arthritis	0.00206	0.0249	CbGeAlD
Bortezomib—PSMB2—connective tissue—rheumatoid arthritis	0.00198	0.024	CbGeAlD
Bortezomib—SLC31A1—parotid gland—rheumatoid arthritis	0.00195	0.0237	CbGeAlD
Bortezomib—PSMD2—lymphoid tissue—rheumatoid arthritis	0.00194	0.0235	CbGeAlD
Bortezomib—PSMD2—digestive system—rheumatoid arthritis	0.00191	0.0232	CbGeAlD
Bortezomib—SLC31A1—saliva-secreting gland—rheumatoid arthritis	0.00187	0.0227	CbGeAlD
Bortezomib—PSMD2—tendon—rheumatoid arthritis	0.00182	0.0221	CbGeAlD
Bortezomib—PSMB8—tendon—rheumatoid arthritis	0.00181	0.0219	CbGeAlD
Bortezomib—PSMB5—tendon—rheumatoid arthritis	0.0016	0.0194	CbGeAlD
Bortezomib—PSMB1—lymphoid tissue—rheumatoid arthritis	0.00149	0.018	CbGeAlD
Bortezomib—PSMB1—digestive system—rheumatoid arthritis	0.00147	0.0178	CbGeAlD
Bortezomib—PSMB2—lymphoid tissue—rheumatoid arthritis	0.00145	0.0176	CbGeAlD
Bortezomib—PSMB2—digestive system—rheumatoid arthritis	0.00143	0.0174	CbGeAlD
Bortezomib—PSMB1—tendon—rheumatoid arthritis	0.0014	0.0169	CbGeAlD
Bortezomib—PSMB2—tendon—rheumatoid arthritis	0.00136	0.0165	CbGeAlD
Bortezomib—SLC31A1—digestive system—rheumatoid arthritis	0.00124	0.015	CbGeAlD
Bortezomib—SLC31A1—tendon—rheumatoid arthritis	0.00118	0.0143	CbGeAlD
Bortezomib—PSMB8—Balsalazide—Sulfasalazine—rheumatoid arthritis	0.000822	0.127	CbGdCrCtD
Bortezomib—CYP1A1—parotid gland—rheumatoid arthritis	0.000663	0.00804	CbGeAlD
Bortezomib—CYP2C19—digestive system—rheumatoid arthritis	0.000523	0.00634	CbGeAlD
Bortezomib—PTGS1—connective tissue—rheumatoid arthritis	0.000512	0.00621	CbGeAlD
Bortezomib—CYP1A2—digestive system—rheumatoid arthritis	0.000427	0.00518	CbGeAlD
Bortezomib—CYP1A1—digestive system—rheumatoid arthritis	0.000421	0.00511	CbGeAlD
Bortezomib—CYP2C9—digestive system—rheumatoid arthritis	0.000405	0.00492	CbGeAlD
Bortezomib—PTGS1—digestive system—rheumatoid arthritis	0.00037	0.00449	CbGeAlD
Bortezomib—PTGS1—tendon—rheumatoid arthritis	0.000352	0.00427	CbGeAlD
Bortezomib—CYP3A4—digestive system—rheumatoid arthritis	0.000309	0.00375	CbGeAlD
Bortezomib—CYP2D6—digestive system—rheumatoid arthritis	0.000304	0.00369	CbGeAlD
Bortezomib—PSMB8—Medrysone—Hydrocortisone—rheumatoid arthritis	0.000233	0.036	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Methylprednisolone—rheumatoid arthritis	0.000221	0.0341	CbGdCrCtD
Bortezomib—PSMB8—Medrysone—Methylprednisolone—rheumatoid arthritis	0.00022	0.0339	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Dexamethasone—rheumatoid arthritis	0.000218	0.0336	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Betamethasone—rheumatoid arthritis	0.000218	0.0336	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Triamcinolone—rheumatoid arthritis	0.000213	0.0328	CbGdCrCtD
Bortezomib—PSMB8—Medrysone—Prednisolone—rheumatoid arthritis	0.000196	0.0302	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Hydrocortisone—rheumatoid arthritis	0.000169	0.026	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Methylprednisolone—rheumatoid arthritis	0.000159	0.0246	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Betamethasone—rheumatoid arthritis	0.000157	0.0242	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Dexamethasone—rheumatoid arthritis	0.000157	0.0242	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Triamcinolone—rheumatoid arthritis	0.000153	0.0236	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Prednisone—rheumatoid arthritis	0.000145	0.0224	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Prednisolone—rheumatoid arthritis	0.000142	0.0219	CbGdCrCtD
Bortezomib—PSMB8—Testosterone Propionate—Hydrocortisone—rheumatoid arthritis	0.00013	0.02	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Methylprednisolone—rheumatoid arthritis	0.000121	0.0187	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Dexamethasone—rheumatoid arthritis	0.000119	0.0184	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Betamethasone—rheumatoid arthritis	0.000119	0.0184	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Hydrocortisone—rheumatoid arthritis	0.000119	0.0183	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Hydrocortisone—rheumatoid arthritis	0.000119	0.0183	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Triamcinolone—rheumatoid arthritis	0.000117	0.018	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Methylprednisolone—rheumatoid arthritis	0.000112	0.0173	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Methylprednisolone—rheumatoid arthritis	0.000112	0.0173	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Prednisone—rheumatoid arthritis	0.000111	0.0171	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Dexamethasone—rheumatoid arthritis	0.00011	0.017	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Betamethasone—rheumatoid arthritis	0.00011	0.017	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Prednisolone—rheumatoid arthritis	0.000108	0.0167	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Triamcinolone—rheumatoid arthritis	0.000108	0.0166	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Triamcinolone—rheumatoid arthritis	0.000108	0.0166	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Prednisone—rheumatoid arthritis	0.000102	0.0158	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Prednisone—rheumatoid arthritis	0.000102	0.0158	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Prednisolone—rheumatoid arthritis	9.99e-05	0.0154	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Prednisolone—rheumatoid arthritis	9.99e-05	0.0154	CbGdCrCtD
Bortezomib—PSMB8—Norethindrone—Hydrocortisone—rheumatoid arthritis	9.73e-05	0.015	CbGdCrCtD
Bortezomib—PSMB8—Levonorgestrel—Hydrocortisone—rheumatoid arthritis	7.74e-05	0.0119	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Hydrocortisone—rheumatoid arthritis	6.9e-05	0.0106	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Hydrocortisone—rheumatoid arthritis	6.9e-05	0.0106	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Methylprednisolone—rheumatoid arthritis	6.51e-05	0.01	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Methylprednisolone—rheumatoid arthritis	6.51e-05	0.01	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Betamethasone—rheumatoid arthritis	6.4e-05	0.00988	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Dexamethasone—rheumatoid arthritis	6.4e-05	0.00988	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Triamcinolone—rheumatoid arthritis	6.26e-05	0.00965	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Triamcinolone—rheumatoid arthritis	6.26e-05	0.00965	CbGdCrCtD
Bortezomib—Hepatitis—Methotrexate—rheumatoid arthritis	6.23e-05	0.00022	CcSEcCtD
Bortezomib—Decreased appetite—Hydrocortisone—rheumatoid arthritis	6.19e-05	0.000218	CcSEcCtD
Bortezomib—Nausea—Leflunomide—rheumatoid arthritis	6.17e-05	0.000217	CcSEcCtD
Bortezomib—Urinary tract disorder—Methotrexate—rheumatoid arthritis	6.15e-05	0.000217	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Hydrocortisone—rheumatoid arthritis	6.15e-05	0.000217	CcSEcCtD
Bortezomib—Fatigue—Hydrocortisone—rheumatoid arthritis	6.14e-05	0.000216	CcSEcCtD
Bortezomib—Vision blurred—Prednisone—rheumatoid arthritis	6.12e-05	0.000216	CcSEcCtD
Bortezomib—Urethral disorder—Methotrexate—rheumatoid arthritis	6.11e-05	0.000215	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Triamcinolone—rheumatoid arthritis	6.11e-05	0.000215	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methylprednisolone—rheumatoid arthritis	6.09e-05	0.000215	CcSEcCtD
Bortezomib—Pain—Hydrocortisone—rheumatoid arthritis	6.09e-05	0.000215	CcSEcCtD
Bortezomib—Anaphylactic shock—Dexamethasone—rheumatoid arthritis	6.08e-05	0.000214	CcSEcCtD
Bortezomib—Anaphylactic shock—Betamethasone—rheumatoid arthritis	6.08e-05	0.000214	CcSEcCtD
Bortezomib—Oedema—Dexamethasone—rheumatoid arthritis	6.08e-05	0.000214	CcSEcCtD
Bortezomib—Oedema—Betamethasone—rheumatoid arthritis	6.08e-05	0.000214	CcSEcCtD
Bortezomib—Insomnia—Triamcinolone—rheumatoid arthritis	6.06e-05	0.000214	CcSEcCtD
Bortezomib—Insomnia—Methylprednisolone—rheumatoid arthritis	6.05e-05	0.000213	CcSEcCtD
Bortezomib—Infection—Dexamethasone—rheumatoid arthritis	6.04e-05	0.000213	CcSEcCtD
Bortezomib—Infection—Betamethasone—rheumatoid arthritis	6.04e-05	0.000213	CcSEcCtD
Bortezomib—Ill-defined disorder—Prednisone—rheumatoid arthritis	6.02e-05	0.000212	CcSEcCtD
Bortezomib—Paraesthesia—Triamcinolone—rheumatoid arthritis	6.02e-05	0.000212	CcSEcCtD
Bortezomib—Feeling abnormal—Prednisolone—rheumatoid arthritis	6.01e-05	0.000212	CcSEcCtD
Bortezomib—Paraesthesia—Methylprednisolone—rheumatoid arthritis	6.01e-05	0.000212	CcSEcCtD
Bortezomib—Visual impairment—Methotrexate—rheumatoid arthritis	6e-05	0.000212	CcSEcCtD
Bortezomib—Anaemia—Prednisone—rheumatoid arthritis	6e-05	0.000211	CcSEcCtD
Bortezomib—Shock—Dexamethasone—rheumatoid arthritis	5.98e-05	0.000211	CcSEcCtD
Bortezomib—Shock—Betamethasone—rheumatoid arthritis	5.98e-05	0.000211	CcSEcCtD
Bortezomib—Dyspnoea—Triamcinolone—rheumatoid arthritis	5.98e-05	0.000211	CcSEcCtD
Bortezomib—Nervous system disorder—Dexamethasone—rheumatoid arthritis	5.97e-05	0.00021	CcSEcCtD
Bortezomib—Nervous system disorder—Betamethasone—rheumatoid arthritis	5.97e-05	0.00021	CcSEcCtD
Bortezomib—Agitation—Prednisone—rheumatoid arthritis	5.96e-05	0.00021	CcSEcCtD
Bortezomib—Thrombocytopenia—Betamethasone—rheumatoid arthritis	5.96e-05	0.00021	CcSEcCtD
Bortezomib—Thrombocytopenia—Dexamethasone—rheumatoid arthritis	5.96e-05	0.00021	CcSEcCtD
Bortezomib—PSMB8—Dexamethasone—Prednisone—rheumatoid arthritis	5.94e-05	0.00916	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Prednisone—rheumatoid arthritis	5.94e-05	0.00916	CbGdCrCtD
Bortezomib—Tachycardia—Betamethasone—rheumatoid arthritis	5.94e-05	0.000209	CcSEcCtD
Bortezomib—Tachycardia—Dexamethasone—rheumatoid arthritis	5.94e-05	0.000209	CcSEcCtD
Bortezomib—Angioedema—Prednisone—rheumatoid arthritis	5.93e-05	0.000209	CcSEcCtD
Bortezomib—Hypersensitivity—Cyclosporine—rheumatoid arthritis	5.9e-05	0.000208	CcSEcCtD
Bortezomib—Dyspepsia—Triamcinolone—rheumatoid arthritis	5.9e-05	0.000208	CcSEcCtD
Bortezomib—Erythema multiforme—Methotrexate—rheumatoid arthritis	5.89e-05	0.000208	CcSEcCtD
Bortezomib—Dyspepsia—Methylprednisolone—rheumatoid arthritis	5.89e-05	0.000207	CcSEcCtD
Bortezomib—Hyperhidrosis—Betamethasone—rheumatoid arthritis	5.88e-05	0.000207	CcSEcCtD
Bortezomib—Hyperhidrosis—Dexamethasone—rheumatoid arthritis	5.88e-05	0.000207	CcSEcCtD
Bortezomib—Feeling abnormal—Hydrocortisone—rheumatoid arthritis	5.87e-05	0.000207	CcSEcCtD
Bortezomib—Malaise—Prednisone—rheumatoid arthritis	5.85e-05	0.000206	CcSEcCtD
Bortezomib—Vertigo—Prednisone—rheumatoid arthritis	5.83e-05	0.000205	CcSEcCtD
Bortezomib—Eye disorder—Methotrexate—rheumatoid arthritis	5.82e-05	0.000205	CcSEcCtD
Bortezomib—Gastrointestinal pain—Hydrocortisone—rheumatoid arthritis	5.82e-05	0.000205	CcSEcCtD
Bortezomib—Syncope—Prednisone—rheumatoid arthritis	5.82e-05	0.000205	CcSEcCtD
Bortezomib—Tinnitus—Methotrexate—rheumatoid arthritis	5.81e-05	0.000205	CcSEcCtD
Bortezomib—Anorexia—Dexamethasone—rheumatoid arthritis	5.8e-05	0.000204	CcSEcCtD
Bortezomib—Anorexia—Betamethasone—rheumatoid arthritis	5.8e-05	0.000204	CcSEcCtD
Bortezomib—PSMB8—Dexamethasone—Prednisolone—rheumatoid arthritis	5.8e-05	0.00894	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Prednisolone—rheumatoid arthritis	5.8e-05	0.00894	CbGdCrCtD
Bortezomib—Urticaria—Prednisolone—rheumatoid arthritis	5.79e-05	0.000204	CcSEcCtD
Bortezomib—Cardiac disorder—Methotrexate—rheumatoid arthritis	5.78e-05	0.000204	CcSEcCtD
Bortezomib—Fatigue—Triamcinolone—rheumatoid arthritis	5.78e-05	0.000204	CcSEcCtD
Bortezomib—Fatigue—Methylprednisolone—rheumatoid arthritis	5.77e-05	0.000203	CcSEcCtD
Bortezomib—Asthenia—Cyclosporine—rheumatoid arthritis	5.75e-05	0.000203	CcSEcCtD
Bortezomib—Pain—Triamcinolone—rheumatoid arthritis	5.73e-05	0.000202	CcSEcCtD
Bortezomib—Loss of consciousness—Prednisone—rheumatoid arthritis	5.7e-05	0.000201	CcSEcCtD
Bortezomib—Hypotension—Betamethasone—rheumatoid arthritis	5.68e-05	0.0002	CcSEcCtD
Bortezomib—Hypotension—Dexamethasone—rheumatoid arthritis	5.68e-05	0.0002	CcSEcCtD
Bortezomib—Pruritus—Cyclosporine—rheumatoid arthritis	5.67e-05	0.0002	CcSEcCtD
Bortezomib—Urticaria—Hydrocortisone—rheumatoid arthritis	5.66e-05	0.000199	CcSEcCtD
Bortezomib—Angiopathy—Methotrexate—rheumatoid arthritis	5.65e-05	0.000199	CcSEcCtD
Bortezomib—Immune system disorder—Methotrexate—rheumatoid arthritis	5.63e-05	0.000198	CcSEcCtD
Bortezomib—Body temperature increased—Hydrocortisone—rheumatoid arthritis	5.63e-05	0.000198	CcSEcCtD
Bortezomib—Abdominal pain—Hydrocortisone—rheumatoid arthritis	5.63e-05	0.000198	CcSEcCtD
Bortezomib—Convulsion—Prednisone—rheumatoid arthritis	5.62e-05	0.000198	CcSEcCtD
Bortezomib—Mediastinal disorder—Methotrexate—rheumatoid arthritis	5.62e-05	0.000198	CcSEcCtD
Bortezomib—Hypertension—Prednisone—rheumatoid arthritis	5.6e-05	0.000197	CcSEcCtD
Bortezomib—Chills—Methotrexate—rheumatoid arthritis	5.59e-05	0.000197	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Dexamethasone—rheumatoid arthritis	5.54e-05	0.000195	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Betamethasone—rheumatoid arthritis	5.54e-05	0.000195	CcSEcCtD
Bortezomib—Arthralgia—Prednisone—rheumatoid arthritis	5.53e-05	0.000195	CcSEcCtD
Bortezomib—Myalgia—Prednisone—rheumatoid arthritis	5.53e-05	0.000195	CcSEcCtD
Bortezomib—Feeling abnormal—Triamcinolone—rheumatoid arthritis	5.52e-05	0.000195	CcSEcCtD
Bortezomib—Feeling abnormal—Methylprednisolone—rheumatoid arthritis	5.51e-05	0.000194	CcSEcCtD
Bortezomib—Anxiety—Prednisone—rheumatoid arthritis	5.51e-05	0.000194	CcSEcCtD
Bortezomib—Insomnia—Betamethasone—rheumatoid arthritis	5.5e-05	0.000194	CcSEcCtD
Bortezomib—Insomnia—Dexamethasone—rheumatoid arthritis	5.5e-05	0.000194	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—rheumatoid arthritis	5.49e-05	0.000193	CcSEcCtD
Bortezomib—Diarrhoea—Cyclosporine—rheumatoid arthritis	5.48e-05	0.000193	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methylprednisolone—rheumatoid arthritis	5.47e-05	0.000193	CcSEcCtD
Bortezomib—Paraesthesia—Dexamethasone—rheumatoid arthritis	5.46e-05	0.000192	CcSEcCtD
Bortezomib—Paraesthesia—Betamethasone—rheumatoid arthritis	5.46e-05	0.000192	CcSEcCtD
Bortezomib—Discomfort—Prednisone—rheumatoid arthritis	5.46e-05	0.000192	CcSEcCtD
Bortezomib—Mental disorder—Methotrexate—rheumatoid arthritis	5.46e-05	0.000192	CcSEcCtD
Bortezomib—Malnutrition—Methotrexate—rheumatoid arthritis	5.42e-05	0.000191	CcSEcCtD
Bortezomib—Erythema—Methotrexate—rheumatoid arthritis	5.42e-05	0.000191	CcSEcCtD
Bortezomib—Hypersensitivity—Prednisolone—rheumatoid arthritis	5.37e-05	0.000189	CcSEcCtD
Bortezomib—Dyspepsia—Betamethasone—rheumatoid arthritis	5.35e-05	0.000189	CcSEcCtD
Bortezomib—Dyspepsia—Dexamethasone—rheumatoid arthritis	5.35e-05	0.000189	CcSEcCtD
Bortezomib—Urticaria—Triamcinolone—rheumatoid arthritis	5.33e-05	0.000188	CcSEcCtD
Bortezomib—Urticaria—Methylprednisolone—rheumatoid arthritis	5.31e-05	0.000187	CcSEcCtD
Bortezomib—Dysgeusia—Methotrexate—rheumatoid arthritis	5.31e-05	0.000187	CcSEcCtD
Bortezomib—Body temperature increased—Triamcinolone—rheumatoid arthritis	5.3e-05	0.000187	CcSEcCtD
Bortezomib—Dizziness—Cyclosporine—rheumatoid arthritis	5.3e-05	0.000187	CcSEcCtD
Bortezomib—Oedema—Prednisone—rheumatoid arthritis	5.3e-05	0.000187	CcSEcCtD
Bortezomib—Anaphylactic shock—Prednisone—rheumatoid arthritis	5.3e-05	0.000187	CcSEcCtD
Bortezomib—Abdominal pain—Methylprednisolone—rheumatoid arthritis	5.29e-05	0.000186	CcSEcCtD
Bortezomib—Decreased appetite—Betamethasone—rheumatoid arthritis	5.29e-05	0.000186	CcSEcCtD
Bortezomib—Decreased appetite—Dexamethasone—rheumatoid arthritis	5.29e-05	0.000186	CcSEcCtD
Bortezomib—Infection—Prednisone—rheumatoid arthritis	5.26e-05	0.000185	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Dexamethasone—rheumatoid arthritis	5.25e-05	0.000185	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Betamethasone—rheumatoid arthritis	5.25e-05	0.000185	CcSEcCtD
Bortezomib—Back pain—Methotrexate—rheumatoid arthritis	5.25e-05	0.000185	CcSEcCtD
Bortezomib—Hypersensitivity—Hydrocortisone—rheumatoid arthritis	5.25e-05	0.000185	CcSEcCtD
Bortezomib—Fatigue—Dexamethasone—rheumatoid arthritis	5.24e-05	0.000185	CcSEcCtD
Bortezomib—Fatigue—Betamethasone—rheumatoid arthritis	5.24e-05	0.000185	CcSEcCtD
Bortezomib—Shock—Prednisone—rheumatoid arthritis	5.21e-05	0.000184	CcSEcCtD
Bortezomib—Pain—Dexamethasone—rheumatoid arthritis	5.2e-05	0.000183	CcSEcCtD
Bortezomib—Pain—Betamethasone—rheumatoid arthritis	5.2e-05	0.000183	CcSEcCtD
Bortezomib—Nervous system disorder—Prednisone—rheumatoid arthritis	5.19e-05	0.000183	CcSEcCtD
Bortezomib—Tachycardia—Prednisone—rheumatoid arthritis	5.17e-05	0.000182	CcSEcCtD
Bortezomib—Skin disorder—Prednisone—rheumatoid arthritis	5.15e-05	0.000181	CcSEcCtD
Bortezomib—Hyperhidrosis—Prednisone—rheumatoid arthritis	5.12e-05	0.00018	CcSEcCtD
Bortezomib—Vision blurred—Methotrexate—rheumatoid arthritis	5.11e-05	0.00018	CcSEcCtD
Bortezomib—Asthenia—Hydrocortisone—rheumatoid arthritis	5.11e-05	0.00018	CcSEcCtD
Bortezomib—Vomiting—Cyclosporine—rheumatoid arthritis	5.09e-05	0.000179	CcSEcCtD
Bortezomib—Rash—Cyclosporine—rheumatoid arthritis	5.05e-05	0.000178	CcSEcCtD
Bortezomib—Anorexia—Prednisone—rheumatoid arthritis	5.05e-05	0.000178	CcSEcCtD
Bortezomib—Dermatitis—Cyclosporine—rheumatoid arthritis	5.05e-05	0.000178	CcSEcCtD
Bortezomib—Pruritus—Hydrocortisone—rheumatoid arthritis	5.04e-05	0.000177	CcSEcCtD
Bortezomib—Ill-defined disorder—Methotrexate—rheumatoid arthritis	5.03e-05	0.000177	CcSEcCtD
Bortezomib—Headache—Cyclosporine—rheumatoid arthritis	5.02e-05	0.000177	CcSEcCtD
Bortezomib—Anaemia—Methotrexate—rheumatoid arthritis	5.01e-05	0.000177	CcSEcCtD
Bortezomib—Feeling abnormal—Betamethasone—rheumatoid arthritis	5.01e-05	0.000177	CcSEcCtD
Bortezomib—Feeling abnormal—Dexamethasone—rheumatoid arthritis	5.01e-05	0.000177	CcSEcCtD
Bortezomib—Gastrointestinal pain—Betamethasone—rheumatoid arthritis	4.97e-05	0.000175	CcSEcCtD
Bortezomib—Gastrointestinal pain—Dexamethasone—rheumatoid arthritis	4.97e-05	0.000175	CcSEcCtD
Bortezomib—Hypersensitivity—Triamcinolone—rheumatoid arthritis	4.94e-05	0.000174	CcSEcCtD
Bortezomib—Hypersensitivity—Methylprednisolone—rheumatoid arthritis	4.93e-05	0.000174	CcSEcCtD
Bortezomib—Malaise—Methotrexate—rheumatoid arthritis	4.89e-05	0.000172	CcSEcCtD
Bortezomib—Vertigo—Methotrexate—rheumatoid arthritis	4.87e-05	0.000172	CcSEcCtD
Bortezomib—Diarrhoea—Hydrocortisone—rheumatoid arthritis	4.87e-05	0.000172	CcSEcCtD
Bortezomib—Leukopenia—Methotrexate—rheumatoid arthritis	4.86e-05	0.000171	CcSEcCtD
Bortezomib—Urticaria—Dexamethasone—rheumatoid arthritis	4.83e-05	0.00017	CcSEcCtD
Bortezomib—Urticaria—Betamethasone—rheumatoid arthritis	4.83e-05	0.00017	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Prednisone—rheumatoid arthritis	4.83e-05	0.00017	CcSEcCtD
Bortezomib—Dizziness—Prednisolone—rheumatoid arthritis	4.82e-05	0.00017	CcSEcCtD
Bortezomib—Asthenia—Triamcinolone—rheumatoid arthritis	4.81e-05	0.000169	CcSEcCtD
Bortezomib—Abdominal pain—Betamethasone—rheumatoid arthritis	4.81e-05	0.000169	CcSEcCtD
Bortezomib—Body temperature increased—Betamethasone—rheumatoid arthritis	4.81e-05	0.000169	CcSEcCtD
Bortezomib—Body temperature increased—Dexamethasone—rheumatoid arthritis	4.81e-05	0.000169	CcSEcCtD
Bortezomib—Abdominal pain—Dexamethasone—rheumatoid arthritis	4.81e-05	0.000169	CcSEcCtD
Bortezomib—Asthenia—Methylprednisolone—rheumatoid arthritis	4.8e-05	0.000169	CcSEcCtD
Bortezomib—Insomnia—Prednisone—rheumatoid arthritis	4.79e-05	0.000169	CcSEcCtD
Bortezomib—Nausea—Cyclosporine—rheumatoid arthritis	4.76e-05	0.000168	CcSEcCtD
Bortezomib—Paraesthesia—Prednisone—rheumatoid arthritis	4.76e-05	0.000168	CcSEcCtD
Bortezomib—Pruritus—Triamcinolone—rheumatoid arthritis	4.74e-05	0.000167	CcSEcCtD
Bortezomib—Cough—Methotrexate—rheumatoid arthritis	4.73e-05	0.000167	CcSEcCtD
Bortezomib—Pruritus—Methylprednisolone—rheumatoid arthritis	4.73e-05	0.000167	CcSEcCtD
Bortezomib—Dizziness—Hydrocortisone—rheumatoid arthritis	4.71e-05	0.000166	CcSEcCtD
Bortezomib—Convulsion—Methotrexate—rheumatoid arthritis	4.7e-05	0.000166	CcSEcCtD
Bortezomib—Dyspepsia—Prednisone—rheumatoid arthritis	4.66e-05	0.000164	CcSEcCtD
Bortezomib—Chest pain—Methotrexate—rheumatoid arthritis	4.62e-05	0.000163	CcSEcCtD
Bortezomib—Arthralgia—Methotrexate—rheumatoid arthritis	4.62e-05	0.000163	CcSEcCtD
Bortezomib—Myalgia—Methotrexate—rheumatoid arthritis	4.62e-05	0.000163	CcSEcCtD
Bortezomib—Decreased appetite—Prednisone—rheumatoid arthritis	4.6e-05	0.000162	CcSEcCtD
Bortezomib—Rash—Prednisolone—rheumatoid arthritis	4.6e-05	0.000162	CcSEcCtD
Bortezomib—Dermatitis—Prednisolone—rheumatoid arthritis	4.59e-05	0.000162	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—rheumatoid arthritis	4.59e-05	0.000162	CcSEcCtD
Bortezomib—Diarrhoea—Methylprednisolone—rheumatoid arthritis	4.58e-05	0.000161	CcSEcCtD
Bortezomib—Fatigue—Prednisone—rheumatoid arthritis	4.57e-05	0.000161	CcSEcCtD
Bortezomib—Headache—Prednisolone—rheumatoid arthritis	4.57e-05	0.000161	CcSEcCtD
Bortezomib—Discomfort—Methotrexate—rheumatoid arthritis	4.56e-05	0.000161	CcSEcCtD
Bortezomib—Constipation—Prednisone—rheumatoid arthritis	4.53e-05	0.00016	CcSEcCtD
Bortezomib—Vomiting—Hydrocortisone—rheumatoid arthritis	4.53e-05	0.000159	CcSEcCtD
Bortezomib—Rash—Hydrocortisone—rheumatoid arthritis	4.49e-05	0.000158	CcSEcCtD
Bortezomib—Dermatitis—Hydrocortisone—rheumatoid arthritis	4.48e-05	0.000158	CcSEcCtD
Bortezomib—Confusional state—Methotrexate—rheumatoid arthritis	4.46e-05	0.000157	CcSEcCtD
Bortezomib—Headache—Hydrocortisone—rheumatoid arthritis	4.46e-05	0.000157	CcSEcCtD
Bortezomib—Dizziness—Triamcinolone—rheumatoid arthritis	4.43e-05	0.000156	CcSEcCtD
Bortezomib—Anaphylactic shock—Methotrexate—rheumatoid arthritis	4.43e-05	0.000156	CcSEcCtD
Bortezomib—Dizziness—Methylprednisolone—rheumatoid arthritis	4.42e-05	0.000156	CcSEcCtD
Bortezomib—Infection—Methotrexate—rheumatoid arthritis	4.4e-05	0.000155	CcSEcCtD
Bortezomib—Feeling abnormal—Prednisone—rheumatoid arthritis	4.37e-05	0.000154	CcSEcCtD
Bortezomib—Asthenia—Betamethasone—rheumatoid arthritis	4.36e-05	0.000154	CcSEcCtD
Bortezomib—Asthenia—Dexamethasone—rheumatoid arthritis	4.36e-05	0.000154	CcSEcCtD
Bortezomib—Nervous system disorder—Methotrexate—rheumatoid arthritis	4.34e-05	0.000153	CcSEcCtD
Bortezomib—Thrombocytopenia—Methotrexate—rheumatoid arthritis	4.33e-05	0.000153	CcSEcCtD
Bortezomib—Gastrointestinal pain—Prednisone—rheumatoid arthritis	4.33e-05	0.000153	CcSEcCtD
Bortezomib—Nausea—Prednisolone—rheumatoid arthritis	4.33e-05	0.000153	CcSEcCtD
Bortezomib—Pruritus—Dexamethasone—rheumatoid arthritis	4.3e-05	0.000152	CcSEcCtD
Bortezomib—Pruritus—Betamethasone—rheumatoid arthritis	4.3e-05	0.000152	CcSEcCtD
Bortezomib—Skin disorder—Methotrexate—rheumatoid arthritis	4.3e-05	0.000152	CcSEcCtD
Bortezomib—Hyperhidrosis—Methotrexate—rheumatoid arthritis	4.28e-05	0.000151	CcSEcCtD
Bortezomib—Vomiting—Triamcinolone—rheumatoid arthritis	4.26e-05	0.00015	CcSEcCtD
Bortezomib—Vomiting—Methylprednisolone—rheumatoid arthritis	4.25e-05	0.00015	CcSEcCtD
Bortezomib—Nausea—Hydrocortisone—rheumatoid arthritis	4.23e-05	0.000149	CcSEcCtD
Bortezomib—Rash—Triamcinolone—rheumatoid arthritis	4.23e-05	0.000149	CcSEcCtD
Bortezomib—Dermatitis—Triamcinolone—rheumatoid arthritis	4.22e-05	0.000149	CcSEcCtD
Bortezomib—Anorexia—Methotrexate—rheumatoid arthritis	4.22e-05	0.000149	CcSEcCtD
Bortezomib—Rash—Methylprednisolone—rheumatoid arthritis	4.22e-05	0.000149	CcSEcCtD
Bortezomib—Dermatitis—Methylprednisolone—rheumatoid arthritis	4.21e-05	0.000148	CcSEcCtD
Bortezomib—Urticaria—Prednisone—rheumatoid arthritis	4.21e-05	0.000148	CcSEcCtD
Bortezomib—Headache—Triamcinolone—rheumatoid arthritis	4.2e-05	0.000148	CcSEcCtD
Bortezomib—Headache—Methylprednisolone—rheumatoid arthritis	4.19e-05	0.000148	CcSEcCtD
Bortezomib—Abdominal pain—Prednisone—rheumatoid arthritis	4.19e-05	0.000148	CcSEcCtD
Bortezomib—Body temperature increased—Prednisone—rheumatoid arthritis	4.19e-05	0.000148	CcSEcCtD
Bortezomib—Diarrhoea—Dexamethasone—rheumatoid arthritis	4.16e-05	0.000147	CcSEcCtD
Bortezomib—Diarrhoea—Betamethasone—rheumatoid arthritis	4.16e-05	0.000147	CcSEcCtD
Bortezomib—Hypotension—Methotrexate—rheumatoid arthritis	4.14e-05	0.000146	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methotrexate—rheumatoid arthritis	4.03e-05	0.000142	CcSEcCtD
Bortezomib—Dizziness—Dexamethasone—rheumatoid arthritis	4.02e-05	0.000142	CcSEcCtD
Bortezomib—Dizziness—Betamethasone—rheumatoid arthritis	4.02e-05	0.000142	CcSEcCtD
Bortezomib—Insomnia—Methotrexate—rheumatoid arthritis	4e-05	0.000141	CcSEcCtD
Bortezomib—Nausea—Triamcinolone—rheumatoid arthritis	3.98e-05	0.00014	CcSEcCtD
Bortezomib—Paraesthesia—Methotrexate—rheumatoid arthritis	3.98e-05	0.00014	CcSEcCtD
Bortezomib—Nausea—Methylprednisolone—rheumatoid arthritis	3.97e-05	0.00014	CcSEcCtD
Bortezomib—Dyspnoea—Methotrexate—rheumatoid arthritis	3.95e-05	0.000139	CcSEcCtD
Bortezomib—Hypersensitivity—Prednisone—rheumatoid arthritis	3.9e-05	0.000138	CcSEcCtD
Bortezomib—Dyspepsia—Methotrexate—rheumatoid arthritis	3.9e-05	0.000137	CcSEcCtD
Bortezomib—Vomiting—Betamethasone—rheumatoid arthritis	3.87e-05	0.000136	CcSEcCtD
Bortezomib—Vomiting—Dexamethasone—rheumatoid arthritis	3.87e-05	0.000136	CcSEcCtD
Bortezomib—Decreased appetite—Methotrexate—rheumatoid arthritis	3.85e-05	0.000136	CcSEcCtD
Bortezomib—Rash—Betamethasone—rheumatoid arthritis	3.84e-05	0.000135	CcSEcCtD
Bortezomib—Rash—Dexamethasone—rheumatoid arthritis	3.84e-05	0.000135	CcSEcCtD
Bortezomib—Dermatitis—Betamethasone—rheumatoid arthritis	3.83e-05	0.000135	CcSEcCtD
Bortezomib—Dermatitis—Dexamethasone—rheumatoid arthritis	3.83e-05	0.000135	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Methotrexate—rheumatoid arthritis	3.82e-05	0.000135	CcSEcCtD
Bortezomib—Fatigue—Methotrexate—rheumatoid arthritis	3.82e-05	0.000134	CcSEcCtD
Bortezomib—Headache—Betamethasone—rheumatoid arthritis	3.81e-05	0.000134	CcSEcCtD
Bortezomib—Headache—Dexamethasone—rheumatoid arthritis	3.81e-05	0.000134	CcSEcCtD
Bortezomib—Asthenia—Prednisone—rheumatoid arthritis	3.8e-05	0.000134	CcSEcCtD
Bortezomib—Pain—Methotrexate—rheumatoid arthritis	3.79e-05	0.000133	CcSEcCtD
Bortezomib—Pruritus—Prednisone—rheumatoid arthritis	3.75e-05	0.000132	CcSEcCtD
Bortezomib—Feeling abnormal—Methotrexate—rheumatoid arthritis	3.65e-05	0.000129	CcSEcCtD
Bortezomib—Diarrhoea—Prednisone—rheumatoid arthritis	3.62e-05	0.000128	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methotrexate—rheumatoid arthritis	3.62e-05	0.000128	CcSEcCtD
Bortezomib—Nausea—Dexamethasone—rheumatoid arthritis	3.61e-05	0.000127	CcSEcCtD
Bortezomib—Nausea—Betamethasone—rheumatoid arthritis	3.61e-05	0.000127	CcSEcCtD
Bortezomib—Urticaria—Methotrexate—rheumatoid arthritis	3.52e-05	0.000124	CcSEcCtD
Bortezomib—Dizziness—Prednisone—rheumatoid arthritis	3.5e-05	0.000123	CcSEcCtD
Bortezomib—Body temperature increased—Methotrexate—rheumatoid arthritis	3.5e-05	0.000123	CcSEcCtD
Bortezomib—Abdominal pain—Methotrexate—rheumatoid arthritis	3.5e-05	0.000123	CcSEcCtD
Bortezomib—Vomiting—Prednisone—rheumatoid arthritis	3.37e-05	0.000119	CcSEcCtD
Bortezomib—Rash—Prednisone—rheumatoid arthritis	3.34e-05	0.000118	CcSEcCtD
Bortezomib—Dermatitis—Prednisone—rheumatoid arthritis	3.34e-05	0.000118	CcSEcCtD
Bortezomib—Headache—Prednisone—rheumatoid arthritis	3.32e-05	0.000117	CcSEcCtD
Bortezomib—Hypersensitivity—Methotrexate—rheumatoid arthritis	3.26e-05	0.000115	CcSEcCtD
Bortezomib—Asthenia—Methotrexate—rheumatoid arthritis	3.18e-05	0.000112	CcSEcCtD
Bortezomib—Nausea—Prednisone—rheumatoid arthritis	3.15e-05	0.000111	CcSEcCtD
Bortezomib—Pruritus—Methotrexate—rheumatoid arthritis	3.13e-05	0.00011	CcSEcCtD
Bortezomib—Diarrhoea—Methotrexate—rheumatoid arthritis	3.03e-05	0.000107	CcSEcCtD
Bortezomib—Dizziness—Methotrexate—rheumatoid arthritis	2.93e-05	0.000103	CcSEcCtD
Bortezomib—Vomiting—Methotrexate—rheumatoid arthritis	2.81e-05	9.92e-05	CcSEcCtD
Bortezomib—Rash—Methotrexate—rheumatoid arthritis	2.79e-05	9.84e-05	CcSEcCtD
Bortezomib—Dermatitis—Methotrexate—rheumatoid arthritis	2.79e-05	9.83e-05	CcSEcCtD
Bortezomib—Headache—Methotrexate—rheumatoid arthritis	2.77e-05	9.77e-05	CcSEcCtD
Bortezomib—Nausea—Methotrexate—rheumatoid arthritis	2.63e-05	9.27e-05	CcSEcCtD
Bortezomib—CYP1A2—Metabolism—PTGES—rheumatoid arthritis	8.81e-06	3.67e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—NOS3—rheumatoid arthritis	8.79e-06	3.66e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—PTGS2—rheumatoid arthritis	8.78e-06	3.66e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—PTGS2—rheumatoid arthritis	8.78e-06	3.66e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—PTGS2—rheumatoid arthritis	8.78e-06	3.66e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL1B—rheumatoid arthritis	8.73e-06	3.63e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—CD4—rheumatoid arthritis	8.72e-06	3.63e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL2—rheumatoid arthritis	8.69e-06	3.62e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ALOX5—rheumatoid arthritis	8.67e-06	3.61e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—PTGS2—rheumatoid arthritis	8.66e-06	3.61e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—BGN—rheumatoid arthritis	8.64e-06	3.6e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—rheumatoid arthritis	8.64e-06	3.6e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—B3GNT2—rheumatoid arthritis	8.57e-06	3.57e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ACP5—rheumatoid arthritis	8.57e-06	3.57e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—MED1—rheumatoid arthritis	8.48e-06	3.53e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—FN1—rheumatoid arthritis	8.47e-06	3.52e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—FN1—rheumatoid arthritis	8.47e-06	3.52e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—FN1—rheumatoid arthritis	8.47e-06	3.52e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6ST—rheumatoid arthritis	8.43e-06	3.51e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6ST—rheumatoid arthritis	8.43e-06	3.51e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6ST—rheumatoid arthritis	8.43e-06	3.51e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—ALB—rheumatoid arthritis	8.41e-06	3.5e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—ALB—rheumatoid arthritis	8.41e-06	3.5e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—ALB—rheumatoid arthritis	8.41e-06	3.5e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—MED1—rheumatoid arthritis	8.4e-06	3.5e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—TGFB1—rheumatoid arthritis	8.38e-06	3.49e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—FN1—rheumatoid arthritis	8.35e-06	3.47e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—TGFB1—rheumatoid arthritis	8.34e-06	3.47e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6ST—rheumatoid arthritis	8.31e-06	3.46e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—TGFB1—rheumatoid arthritis	8.3e-06	3.46e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—ALB—rheumatoid arthritis	8.29e-06	3.45e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—NFKB1—rheumatoid arthritis	8.26e-06	3.44e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—NFKB1—rheumatoid arthritis	8.26e-06	3.44e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—NFKB1—rheumatoid arthritis	8.26e-06	3.44e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PLB1—rheumatoid arthritis	8.19e-06	3.41e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—NFKB1—rheumatoid arthritis	8.14e-06	3.39e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—MAPK8—rheumatoid arthritis	8.12e-06	3.38e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—MAPK8—rheumatoid arthritis	8.12e-06	3.38e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—MAPK8—rheumatoid arthritis	8.12e-06	3.38e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CD80—rheumatoid arthritis	8.12e-06	3.38e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CD80—rheumatoid arthritis	8.12e-06	3.38e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CD80—rheumatoid arthritis	8.12e-06	3.38e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—NOS3—rheumatoid arthritis	8.04e-06	3.35e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—NOS3—rheumatoid arthritis	8.04e-06	3.35e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—NOS3—rheumatoid arthritis	8.04e-06	3.35e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—MAPK8—rheumatoid arthritis	8e-06	3.33e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CD80—rheumatoid arthritis	8e-06	3.33e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ALOX5—rheumatoid arthritis	7.95e-06	3.31e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—NOS3—rheumatoid arthritis	7.93e-06	3.3e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ACP5—rheumatoid arthritis	7.88e-06	3.28e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—B3GNT2—rheumatoid arthritis	7.88e-06	3.28e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CXCL8—rheumatoid arthritis	7.87e-06	3.28e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CXCL8—rheumatoid arthritis	7.83e-06	3.26e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—B3GNT2—rheumatoid arthritis	7.81e-06	3.25e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ACP5—rheumatoid arthritis	7.81e-06	3.25e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CXCL8—rheumatoid arthritis	7.8e-06	3.25e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—BGN—rheumatoid arthritis	7.71e-06	3.21e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—POMC—rheumatoid arthritis	7.71e-06	3.21e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—POMC—rheumatoid arthritis	7.71e-06	3.21e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—POMC—rheumatoid arthritis	7.71e-06	3.21e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PLD4—rheumatoid arthritis	7.7e-06	3.2e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—POMC—rheumatoid arthritis	7.63e-06	3.18e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—POMC—rheumatoid arthritis	7.6e-06	3.17e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCL2—rheumatoid arthritis	7.55e-06	3.14e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCL2—rheumatoid arthritis	7.55e-06	3.14e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCL2—rheumatoid arthritis	7.55e-06	3.14e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6R—rheumatoid arthritis	7.52e-06	3.13e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6R—rheumatoid arthritis	7.52e-06	3.13e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL2—rheumatoid arthritis	7.52e-06	3.13e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6R—rheumatoid arthritis	7.52e-06	3.13e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL2—rheumatoid arthritis	7.49e-06	3.12e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL2—rheumatoid arthritis	7.45e-06	3.1e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCL2—rheumatoid arthritis	7.44e-06	3.1e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ACAN—rheumatoid arthritis	7.43e-06	3.09e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6R—rheumatoid arthritis	7.42e-06	3.09e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PTGS2—rheumatoid arthritis	7.36e-06	3.06e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PTGS2—rheumatoid arthritis	7.36e-06	3.06e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PTGS2—rheumatoid arthritis	7.36e-06	3.06e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PTGS2—rheumatoid arthritis	7.25e-06	3.02e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CAT—rheumatoid arthritis	7.22e-06	3.01e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—MED1—rheumatoid arthritis	7.18e-06	2.99e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MMP9—rheumatoid arthritis	7.12e-06	2.96e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ALOX5—rheumatoid arthritis	7.1e-06	2.95e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—BGN—rheumatoid arthritis	7.09e-06	2.95e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MMP9—rheumatoid arthritis	7.09e-06	2.95e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ENO1—rheumatoid arthritis	7.07e-06	2.94e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MMP9—rheumatoid arthritis	7.05e-06	2.94e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—NFKB1—rheumatoid arthritis	7.04e-06	2.93e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—BGN—rheumatoid arthritis	7.03e-06	2.93e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—NFKB1—rheumatoid arthritis	7.01e-06	2.92e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—rheumatoid arthritis	6.99e-06	2.91e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC25A12—rheumatoid arthritis	6.99e-06	2.91e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—NFKB1—rheumatoid arthritis	6.98e-06	2.9e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—ALB—rheumatoid arthritis	6.96e-06	2.9e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MAPK8—rheumatoid arthritis	6.93e-06	2.88e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MAPK8—rheumatoid arthritis	6.89e-06	2.87e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MAPK8—rheumatoid arthritis	6.86e-06	2.86e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TYK2—rheumatoid arthritis	6.85e-06	2.85e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TYK2—rheumatoid arthritis	6.85e-06	2.85e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TYK2—rheumatoid arthritis	6.85e-06	2.85e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—IL6—rheumatoid arthritis	6.84e-06	2.85e-05	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IL6—rheumatoid arthritis	6.81e-06	2.83e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGES—rheumatoid arthritis	6.8e-06	2.83e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GC—rheumatoid arthritis	6.8e-06	2.83e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IL6—rheumatoid arthritis	6.77e-06	2.82e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TYK2—rheumatoid arthritis	6.76e-06	2.81e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NOS3—rheumatoid arthritis	6.73e-06	2.8e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NOS3—rheumatoid arthritis	6.73e-06	2.8e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NOS3—rheumatoid arthritis	6.73e-06	2.8e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—B3GNT2—rheumatoid arthritis	6.67e-06	2.78e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ACP5—rheumatoid arthritis	6.67e-06	2.78e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NOS3—rheumatoid arthritis	6.63e-06	2.76e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALOX5—rheumatoid arthritis	6.53e-06	2.72e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ENO1—rheumatoid arthritis	6.48e-06	2.7e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALOX5—rheumatoid arthritis	6.47e-06	2.69e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—VEGFA—rheumatoid arthritis	6.39e-06	2.66e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—rheumatoid arthritis	6.38e-06	2.65e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—VEGFA—rheumatoid arthritis	6.36e-06	2.65e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—TGFB1—rheumatoid arthritis	6.35e-06	2.64e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—TGFB1—rheumatoid arthritis	6.35e-06	2.64e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—TGFB1—rheumatoid arthritis	6.35e-06	2.64e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—VEGFA—rheumatoid arthritis	6.33e-06	2.64e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PLB1—rheumatoid arthritis	6.32e-06	2.63e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—IL6—rheumatoid arthritis	6.31e-06	2.63e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—IL6—rheumatoid arthritis	6.28e-06	2.62e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—TGFB1—rheumatoid arthritis	6.26e-06	2.61e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—IL6—rheumatoid arthritis	6.26e-06	2.6e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—rheumatoid arthritis	6.24e-06	2.6e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—rheumatoid arthritis	6.08e-06	2.53e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—MTHFR—rheumatoid arthritis	6.03e-06	2.51e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—BGN—rheumatoid arthritis	6.01e-06	2.5e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CXCL8—rheumatoid arthritis	5.97e-06	2.48e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CXCL8—rheumatoid arthritis	5.97e-06	2.48e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CXCL8—rheumatoid arthritis	5.97e-06	2.48e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CXCL8—rheumatoid arthritis	5.88e-06	2.45e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TGFB1—rheumatoid arthritis	5.87e-06	2.44e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TGFB1—rheumatoid arthritis	5.84e-06	2.43e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TGFB1—rheumatoid arthritis	5.81e-06	2.42e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ENO1—rheumatoid arthritis	5.79e-06	2.41e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL2—rheumatoid arthritis	5.7e-06	2.37e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL2—rheumatoid arthritis	5.7e-06	2.37e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL2—rheumatoid arthritis	5.7e-06	2.37e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—rheumatoid arthritis	5.69e-06	2.37e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—rheumatoid arthritis	5.69e-06	2.37e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL2—rheumatoid arthritis	5.62e-06	2.34e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—rheumatoid arthritis	5.58e-06	2.32e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MED1—rheumatoid arthritis	5.54e-06	2.31e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALOX5—rheumatoid arthritis	5.53e-06	2.3e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MMP9—rheumatoid arthritis	5.4e-06	2.25e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MMP9—rheumatoid arthritis	5.4e-06	2.25e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MMP9—rheumatoid arthritis	5.4e-06	2.25e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NFKB1—rheumatoid arthritis	5.34e-06	2.22e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NFKB1—rheumatoid arthritis	5.34e-06	2.22e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NFKB1—rheumatoid arthritis	5.34e-06	2.22e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ENO1—rheumatoid arthritis	5.32e-06	2.22e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MMP9—rheumatoid arthritis	5.32e-06	2.21e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ENO1—rheumatoid arthritis	5.28e-06	2.2e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NFKB1—rheumatoid arthritis	5.26e-06	2.19e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MAPK8—rheumatoid arthritis	5.25e-06	2.18e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MAPK8—rheumatoid arthritis	5.25e-06	2.18e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MAPK8—rheumatoid arthritis	5.25e-06	2.18e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—rheumatoid arthritis	5.19e-06	2.16e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL6—rheumatoid arthritis	5.18e-06	2.16e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL6—rheumatoid arthritis	5.18e-06	2.16e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL6—rheumatoid arthritis	5.18e-06	2.16e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MAPK8—rheumatoid arthritis	5.17e-06	2.15e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ACP5—rheumatoid arthritis	5.15e-06	2.14e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—B3GNT2—rheumatoid arthritis	5.15e-06	2.14e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL6—rheumatoid arthritis	5.11e-06	2.13e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CAT—rheumatoid arthritis	5.09e-06	2.12e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—rheumatoid arthritis	4.98e-06	2.07e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—rheumatoid arthritis	4.86e-06	2.02e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—VEGFA—rheumatoid arthritis	4.85e-06	2.02e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—VEGFA—rheumatoid arthritis	4.85e-06	2.02e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—VEGFA—rheumatoid arthritis	4.85e-06	2.02e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—rheumatoid arthritis	4.83e-06	2.01e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—POMC—rheumatoid arthritis	4.82e-06	2.01e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—rheumatoid arthritis	4.81e-06	2e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—IL6—rheumatoid arthritis	4.79e-06	1.99e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—IL6—rheumatoid arthritis	4.79e-06	1.99e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—IL6—rheumatoid arthritis	4.79e-06	1.99e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—rheumatoid arthritis	4.79e-06	1.99e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—rheumatoid arthritis	4.78e-06	1.99e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—IL6—rheumatoid arthritis	4.72e-06	1.96e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CAT—rheumatoid arthritis	4.67e-06	1.94e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—BGN—rheumatoid arthritis	4.64e-06	1.93e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—rheumatoid arthritis	4.54e-06	1.89e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ENO1—rheumatoid arthritis	4.51e-06	1.88e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TGFB1—rheumatoid arthritis	4.45e-06	1.85e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TGFB1—rheumatoid arthritis	4.45e-06	1.85e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TGFB1—rheumatoid arthritis	4.45e-06	1.85e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—rheumatoid arthritis	4.43e-06	1.85e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6—rheumatoid arthritis	4.42e-06	1.84e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—rheumatoid arthritis	4.4e-06	1.83e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ALB—rheumatoid arthritis	4.4e-06	1.83e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TGFB1—rheumatoid arthritis	4.38e-06	1.83e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—rheumatoid arthritis	4.38e-06	1.82e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALOX5—rheumatoid arthritis	4.27e-06	1.78e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—MTHFR—rheumatoid arthritis	4.25e-06	1.77e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—NOS3—rheumatoid arthritis	4.21e-06	1.75e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CAT—rheumatoid arthritis	4.17e-06	1.73e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—MTHFR—rheumatoid arthritis	3.89e-06	1.62e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—rheumatoid arthritis	3.88e-06	1.62e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—rheumatoid arthritis	3.85e-06	1.6e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CAT—rheumatoid arthritis	3.83e-06	1.59e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CAT—rheumatoid arthritis	3.8e-06	1.58e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—rheumatoid arthritis	3.66e-06	1.52e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—rheumatoid arthritis	3.66e-06	1.52e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—rheumatoid arthritis	3.66e-06	1.52e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—rheumatoid arthritis	3.61e-06	1.5e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ENO1—rheumatoid arthritis	3.48e-06	1.45e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—MTHFR—rheumatoid arthritis	3.48e-06	1.45e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—POMC—rheumatoid arthritis	3.4e-06	1.41e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—rheumatoid arthritis	3.35e-06	1.4e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—rheumatoid arthritis	3.35e-06	1.4e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—rheumatoid arthritis	3.35e-06	1.4e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—rheumatoid arthritis	3.3e-06	1.38e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CAT—rheumatoid arthritis	3.25e-06	1.35e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—MTHFR—rheumatoid arthritis	3.2e-06	1.33e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—MTHFR—rheumatoid arthritis	3.17e-06	1.32e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—POMC—rheumatoid arthritis	3.11e-06	1.3e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ALB—rheumatoid arthritis	3.1e-06	1.29e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—NOS3—rheumatoid arthritis	2.96e-06	1.23e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ALB—rheumatoid arthritis	2.84e-06	1.18e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—POMC—rheumatoid arthritis	2.78e-06	1.16e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—NOS3—rheumatoid arthritis	2.72e-06	1.13e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—rheumatoid arthritis	2.71e-06	1.13e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—MTHFR—rheumatoid arthritis	2.71e-06	1.13e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—POMC—rheumatoid arthritis	2.56e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—POMC—rheumatoid arthritis	2.54e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ALB—rheumatoid arthritis	2.53e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CAT—rheumatoid arthritis	2.5e-06	1.04e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—rheumatoid arthritis	2.48e-06	1.03e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—NOS3—rheumatoid arthritis	2.42e-06	1.01e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALB—rheumatoid arthritis	2.33e-06	9.7e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALB—rheumatoid arthritis	2.31e-06	9.62e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NOS3—rheumatoid arthritis	2.23e-06	9.28e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—rheumatoid arthritis	2.22e-06	9.23e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NOS3—rheumatoid arthritis	2.21e-06	9.2e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—POMC—rheumatoid arthritis	2.17e-06	9.02e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MTHFR—rheumatoid arthritis	2.09e-06	8.7e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—rheumatoid arthritis	2.04e-06	8.49e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—rheumatoid arthritis	2.02e-06	8.42e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALB—rheumatoid arthritis	1.97e-06	8.22e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NOS3—rheumatoid arthritis	1.89e-06	7.86e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—rheumatoid arthritis	1.73e-06	7.19e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—POMC—rheumatoid arthritis	1.67e-06	6.96e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALB—rheumatoid arthritis	1.52e-06	6.34e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NOS3—rheumatoid arthritis	1.46e-06	6.07e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—rheumatoid arthritis	1.33e-06	5.55e-06	CbGpPWpGaD
